Additionally, si-VDAC1 treatment resulted in modifications to the TME, including decreased angiogenesis, changes in the extracellular matrix (ECM), reduced tumor-associated macrophages, and inhibited stemness and EMT. This evidence concerns the gene VDAC1 and neoplasm.